![]() ![]() ![]() The Exact Diagnostics Bulk Urine Negative is intended to be validated as an independent external quality run control to monitor the absence of Adenovirus (ADV), BK virus (BKV), Candida auris ( C. These products may also help in the detection of errors in laboratory testing procedures, including potential contamination events. Both are matrices designed for spike-in or dilution purposes as well as to be used with molecular assays to monitor their intra- and inter-run performance. With its innovative technology and partnerships with leading pharmaceutical companies, HTGM was well-positioned to capitalize on the growing demand for molecular diagnostics.Bio-Rad Laboratories has expanded its molecular offering of quality controls with the launch of two new Exact Diagnostics products: Bulk Urine Negative and Bulk CSF Negative. The positive price forecast from the analyst and the buy rating from investment analysts suggested that investors were confident about HTGM’s growth potential. ![]() In conclusion, while the current quarter earnings per share for HTGM were negative, the company’s future prospects looked promising. These partnerships would also provide HTGM with access to a wider range of patients, which would be beneficial for its research and development efforts. Moreover, the company had recently announced partnerships with several leading pharmaceutical companies, which would help it expand its reach and increase its revenue. HTGM’s proprietary technology allowed for the rapid and accurate detection of genetic mutations, which was crucial in the diagnosis and treatment of various diseases. The company had been making strides in the field of molecular diagnostics, which was a rapidly growing market. The reporting date for these figures was August 08, 2023.ĭespite the negative earnings per share, investors seemed to be optimistic about HTGM’s future, as evidenced by the positive price forecast from the analyst. However, the current quarter earnings per share for HTGM were reported to be -$1.84, with sales of $1.6 million. This suggested that the company was viewed positively by analysts, and there was optimism about its future prospects. The current consensus among one polled investment analyst was to buy stock in HTGM, and this rating had held steady since March when it was unchanged from a buy rating. This represented a significant increase of 135.29% from the last price of $2.55. According to data from CNN Money, the one analyst offering a 12-month price forecast for HTGM had a median target of $6.00, with a high estimate of $6.00 and a low estimate of $6.00. (HTGM) was closely watched by investors and analysts alike. On May 24, 2023, the stock performance of HTG Molecular Diagnostics Inc. The company does not have any executives to display. In the previous year, the company reported an annual revenue of $6.4 million and an annual profit of -$21.6 million, resulting in a net profit margin of -339.20%. The company’s next reporting date is scheduled for August 8, 2023, with an earnings per share (EPS) forecast of -$1.84 for this quarter. HTGM’s corporate headquarters is located in Tucson, Arizona. These ratios suggest that the stock may be undervalued. The price-to-earnings (P/E) ratio for HTGM is not available (NM), while the price-to-sales ratio is 0.56, and the price-to-book ratio is 1.17. However, the revenue growth for the same period was -28.52%. HTGM’s market capitalization was $6.3 million, and the company reported an earnings growth of 18.14% last year. Throughout the day, the stock traded within a range of $2.55 to $2.70, with a volume of 2,800 shares traded. (HTGM) opened at $2.70, slightly lower than the previous day’s closing price of $2.75. On May 24, 2023, HTG Molecular Diagnostics Inc. (HTGM) Stock Analysis: Undervalued with Promising Earnings Growth The company is determined to take the necessary steps to regain compliance and maintain its position on the Nasdaq stock exchange. has taken action by appealing the delisting determination by Nasdaq. This notice indicates that the company is not in compliance with a listing rule or standard and could potentially be delisted from the Nasdaq stock exchange if it fails to regain compliance. was served with a notice of delisting or failure to meet a continued listing rule or standard from The Nasdaq Stock Market LLC. On May 18, 2023, HTG Molecular Diagnostics, Inc. ![]()
0 Comments
Leave a Reply. |